I’m the Lead of Translational Science at Ataraxis AI, and a Visiting Professor at King’s College London. My scientific focus is translating frontier genomic and AI technologies into clinically meaningful patient benefit and biological discovery.
I have authored publications in several peer-reviewed journals, including first-author articles in Nature Medicine and Nature Cancer. My work has been featured in media outlets such as The Times and Bloomberg. I was recognized by Nature Medicine as ‘at the forefront of medical research’.
Alongside my scientific and clinical responsibilities, I am passionate about mentorship and community engagement. I have supervised several MSc students, all of whom achieved distinction grades, with three nominated for the Dean’s Research Prize for top project marks in their cohorts. I am also committed to patient and public involvement, working with structural heart teams across London to increase access to life-prolonging procedures.
Biography
I began my medical training at the University of Cambridge in 2012, earning an MA in Neuroscience in 2015. I then joined the MB/PhD program at University College London, conducting PhD research between the UCL Cancer Institute and the Francis Crick Institute. My thesis work received international awards, and I was recognized as a Francis Crick Institute Translation Fellow for serving as a role model in translational medicine. I graduated with PhD and MBBS degrees in 2022, then undertook an Academic Foundation training position in Cardiology at King’s College London while also working as a Postdoctoral Fellow at University College London. In 2024, I joined Yale University as a Faculty member in the School of Medicine, and King’s College London as a Visiting Professor.
Research Interests
My doctoral and postdoctoral research centered on refining molecular portraits of cancer in the light of their evolutionary and ecological features, with the goal of advancing genomic diagnostics. In research faculty and industry leadership roles, my interest has broadened to developing digital biomarkers that identify high-risk patients who are currently overlooked, improving algorithm performance in diverse clinical settings, and exploring the underlying pathophysiological mechanisms.
Selected Publications
- Biswas et al. Nature Medicine (2019). A Clonal Expression Biomarker Associates with Lung Cancer Mortality.
- Biswas et al. Nature Cancer (2025). Prospective Validation of ORACLE, a Clonal Expression Biomarker Associated with Survival of Patients with Lung Adenocarcinoma.
- Biswas et al. European Heart Journal - Digital Health (2025). Racial and Ethnic Disparities in Aortic Stenosis within a Universal Healthcare System Characterised by Natural Language Processing for Targeted Intervention.
- Biswas et al. JACC: Advances (2025). Artificial Intelligence for Cardiovascular Care in Action: From Learning to Implementation in Health Systems.